Mode
Text Size
Log in / Sign up

Transcranial direct current stimulation provides modest and short term relief for treatment resistant depressionBrain stimulation shows short term relief for treatment resistant depression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that transcranial direct current stimulation provides only modest and short-term relief in treatment-resistant depression.

The meta-analysis investigated the effectiveness of transcranial direct current stimulation (tDCS) compared to sham tDCS in patients diagnosed with treatment-resistant depression. The primary focus was on evaluating changes in depressive symptoms immediately following the intervention and at a subsequent follow-up point.

The findings indicated that active tDCS led to a significant reduction in depressive symptoms immediately post-treatment when compared to the sham group. However, this improvement did not persist over time, as no significant difference between the active and sham groups was observed during the follow-up period.

The authors noted several limitations regarding the evidence base, including inconsistent findings across studies and high heterogeneity among the included data. Furthermore, the analysis was based on a limited number of small trials, which may impact the overall strength of the conclusions.

Clinically, these results suggest that tDCS may offer modest and short-term benefits for patients with treatment-resistant depression. Given the lack of sustained improvement at follow-up and the heterogeneity of the underlying data, its role as a long-term maintenance therapy remains uncertain.

Living with treatment-resistant depression means standard treatments have failed to provide lasting relief. For these patients, finding any form of progress is vital. A recent look at clinical trials suggests that a method called transcranial direct current stimulation (tDCS) can offer immediate help by using a mild electrical current to stimulate the brain.

The data shows that people receiving active tDCS saw a significant drop in their depressive symptoms immediately after treatment compared to those who received a fake version. However, this relief appears to be short-lived. When researchers checked back with patients 30 days later, there was no significant difference between those who got the real treatment and those who did not.

While these results suggest tDCS can provide quick support, the evidence is still mixed. The study relied on a small number of trials that were very different from one another. Because the findings are inconsistent and based on limited data, it is currently seen as a way to get modest, short-term relief rather than a long-term cure.

What this means for you:
Brain stimulation provides immediate but short-lived relief for people with treatment-resistant depression.

Common questions

How does brain stimulation help with depression?

Transcranial direct current stimulation (tDCS) uses a mild electrical current to stimulate the brain. In this study of patients with treatment-resistant depression, active tDCS significantly reduced depressive symptoms immediately after treatment compared to a sham version.

How long do the effects of this treatment last?

The relief from tDCS appears to be short-term. While patients felt better immediately after treatment, there was no significant difference in symptoms between those who received active tDCS and those who received a sham version at the 30-day follow-up.

Is this a reliable long-term solution for depression?

The evidence is currently limited. Because the study involved small trials with inconsistent findings, tDCS is only considered to provide modest, short-term benefits for those with treatment-resistant depression.

Study Details

Study typeMeta analysis
Sample sizen = 200
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Researchers have studied transcranial direct current stimulation (tDCS) as a possible treatment for major depressive disorder (MDD), especially for people with treatment-resistant depression (TRD). This systematic review and meta-analysis evaluate the effectiveness and safety of tDCS for TRD by analyzing data from randomized clinical trials. METHODS: To evaluate the impact of tDCS on TRD, we adhered to the 2020 PRISMA guidelines and registered our protocol with PROSPERO (CRD42024606468). A comprehensive search was performed using keywords related to tDCS and TRD across six databases, focusing on English-language studies published until June 10, 2024. RCTs were included based on specific PICO criteria, with a thorough risk of bias assessment using the Cochrane ROB-2 tool. Statistical analyses were conducted using Stata-17 software. RESULTS: A total of 448 studies were initially identified, with six studies (200 participants) meeting inclusion criteria for assessing immediate post-treatment effects of tDCS on TRD. Meta-analysis showed active tDCS significantly reduced depressive symptoms compared to sham (SMD: -1.17 [-1.85, -0.49]; P < 0.001). Significant outcome predictors included session number, age, male percentage, and duration. A follow-up analysis of delayed effects (30-day post-treatment), using four studies (154 participants), found no significant difference between active and sham tDCS (SMD: -0.12 [-1.98, 1.74]; P = 0.90). CONCLUSIONS: This review suggests tDCS may provide modest, short-term benefits in TRD, but findings were inconsistent, highly heterogeneous, and based on limited small trials. Standardized, large-scale studies with optimized protocols and longer follow-up are needed to confirm efficacy and safety.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.